WWW - Posts tagged Enzon pharmaceuticals at BloggingStocks

enzon pharmaceuticals posts

Closing Bell: Stocks Jumping In Ahead of Key Earnings (PFE, EK, AAPL, RIMM, ENZN, BAC, KYN, ROSG)

Posted Jan 14th 2010 4:00PM by Jon Ogg (RSS feed)
Filed under: Apple Inc (AAPL), Pfizer (PFE), Bank of America (BAC), Research in Motion (RIMM), Eastman Kodak (EK)

The market held up well considering the news flow today. The jobless claims grew again and the retail sales were far from impressive. We had Obama publicly attacking the banks for more taxes, and even that didn't hurt the bank stocks. A well-received 30-Year Treasury auction helped with those who might spread fear about a bond market bubble as well.

Here are the unofficial closing bell levels:

Dow 10,711.60 +30.83 (0.29%)
S&P 500 1,148.61 +2.93 (0.26%)
Nasdaq 2,318.01 +10.11 (0.44%)

Top Analyst Upgrades/Downgrades
Top Day Trader Alerts
Top Stock Rumors

Continue reading Closing Bell: Stocks Jumping In Ahead of Key Earnings (PFE, EK, AAPL, RIMM, ENZN, BAC, KYN, ROSG)

Icahn eyes Enzon (ENZN): Activist targets biotech

Posted Mar 31st 2008 2:22PM by Steven Halpern (RSS feed)
Filed under: Newsletters, Stocks to Buy

"Carl Icahn - one of Wall Street's most renowned and successful investors - is on another mission; this pitbull is sinking his teeth into one of the companies in our portfolio - Enzon Pharmaceuticals (NASDAQ: ENZN)," notes Marc Lichtenfeld.

In Xcelerated Profits Report, the senior analyst and noted healthcare sector expert takes a look at the small cap biotechnology, which is involved in developing products for the treatment of cancer.

"With an infamous reputation for diving into stocks that he perceives as undervalued and shaking up management teams in order to boost shareholder value, Icahn us one of the best 'business partners' we could have.

"One of the big reasons why we recommended Enzon was because some major institutional investors are clamoring for change at the company. They contend that if Enzon was better at maximizing its true potential, the stock could easily vault from its current undervalued state and generate some real wealth for its shareholders.

Continue reading Icahn eyes Enzon (ENZN): Activist targets biotech